GlassScriptPhysician profile
Michelle Stone
NPI 1093257289
$7,111.54
in general payments reported to CMS, 2019-2025
43 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $1,252 · 2023: $1,552 · 2024: $1,451 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,861 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,860.81 |
| Education | $101.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,144.38 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $903.23 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $481.78 | 2021-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.23 | 2021-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $452.60 | 2021-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $405.64 | 2021-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $331.51 | 2021-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $297.69 | 2021-2025 | |
| Dexcom, INC. | $266.48 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $249.64 | 2022-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $228.59 | 2021-2025 | Verquvo, Steglatro, Segluromet |
| Ardelyx, INC. | $183.88 | 2023-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $159.14 | 2021-2024 | |
| Janssen Biotech, INC. | $134.54 | 2022-2025 | Tremfya |
| Calliditas Therapeutics US INC. | $121.01 | 2023-2025 | Tarpeyo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $102.62 | 2025 | |
| Mallinckrodt Hospital Products INC. | $97.38 | 2023-2025 | Acthar |
| Fresenius USA Marketing, INC. | $92.16 | 2021-2023 | Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $84.61 | 2023-2025 | |
| Argenx US, INC. | $69.02 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Esperion Therapeutics, INC. | $62.71 | 2021-2025 | Nexletol |
| Insulet Corporation | $61.66 | 2023-2025 | Omnipod |
| Cequr Corporation | $61.20 | 2022-2025 | Cequr Simplicity |
| Medtronic, INC. | $60.64 | 2024-2025 | Synchromedii, Minimed 780g |
| Scpharmaceuticals INC. | $60.09 | 2025 | |
| Abbott Laboratories | $54.47 | 2021-2023 | Freestyle Libre |
| Ucb, INC. | $47.06 | 2023-2024 | Cimzia |
| Corcept Therapeutics | $46.60 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $42.66 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $40.09 | 2021-2023 | |
| Ascensia Diabetes Care US INC. | $39.36 | 2025 | |
| Akebia Therapeutics INC | $32.91 | 2023-2025 | Auryxia, Vafseo |
| Ani Pharmaceuticals, INC. | $32.54 | 2022-2025 | Purified Cortrophin Gel |
| Recordati_rare_diseases_inc. | $31.65 | 2024-2025 | Isturisa, Signifor Lar |
| Azurity Pharmaceuticals, INC. | $26.93 | 2023 | Edarbyclor, Edarbi |
| Sequel Med Tech, LLC | $22.26 | 2025 | Twiist |
| Biogen, INC. | $18.28 | 2024 | Vumerity |
| Glaxosmithkline, LLC. | $18.02 | 2025 | Shingrix, Arexvy |
| Amphastar Pharmaceuticals, INC. | $17.12 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.02 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2025 | Eliquis |
| Aurinia Pharma U.S., INC. | $12.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.